The Trump administration is planning to pilot covering weight loss drugs. A longtime healthcare exec moves to a strategic advisory role at General Catalyst.

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural ...

Trump is changing Medicare, mostly focusing on providers. But the biggest impact may come from tariffs and deporting ...

Days after he sent letters instructing top pharmaceutical manufacturers to use a “most favored nation” pricing model for ...

Dr. Mehmet Oz, the Administrator of the Centers for Medicare and Medicaid Services, discussed the impending changes to the ...

Pfizer ( PFE) CEO Albert Bourla said Tuesday he has a "special relationship" with President Trump, cemented during the ...

The Trump administration is considering a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, the ...

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

President Donald Trump is ratcheting up the pressure on major drugmakers to bring their US prices in line with the far lower ...

Several companies, including Oracle and Microsoft, are expected to sign pledges to work on the Trump administration ...